Discontinuation report MYLAN-RABEPRAZOLE
Report ID | 16042 |
Drug Identification Number | 02408406 |
Brand name | MYLAN-RABEPRAZOLE |
Common or Proper name | RABEPRAZOLE |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RABEPRAZOLE SODIUM |
Strength(s) | 20MG |
Dosage form(s) | TABLET (DELAYED-RELEASE) |
Route of administration | ORAL |
Packaging size | 100BT |
ATC code | A02BC |
ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2017-07-12 |
Remaining supply date | 2018-02-28 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | There is no saleable inventory remaining. |
Company comments | Last Lot # 3051408 and Expires 28-Feb-18. Resolved/discontinued in ID 9188 |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2018-02-15 | French | Compare |
v3 | 2018-02-15 | English | Compare |
v2 | 2017-07-17 | French | Compare |
v1 | 2017-07-17 | English | Compare |
Showing 1 to 4 of 4